LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on VTYX stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sam Slutsky has given his Buy rating due to a combination of factors related to Ventyx Biosciences’ promising pipeline and recent data updates. The company is advancing its VTX2735, a peripheral NLRP3 inhibitor, through an open-label Phase 2 study targeting patients with recurrent pericarditis. The upcoming interim results, expected in Q4 2025, will focus on key endpoints such as changes in pain scores and inflammatory markers, which could position VTX2735 favorably between existing treatments like colchicine and rilonacept.
Additionally, Ventyx’s VTX3232, a CNS-penetrant NLRP3 inhibitor, has shown promising results in reducing inflammatory markers in patients with obesity and cardiometabolic risk factors. This success potentially translates to VTX2735 due to similar target coverage. Despite differences in patient populations and baseline conditions, these developments, combined with Ventyx’s financial health and manageable cash burn, contribute to the positive outlook and justify the Buy rating.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $14.00 price target.